Innovation You Can Breathe
RespiRAX Pharma is a Clinical-stage Small Molecule company Developing a Novel Therapeutic Candidate for COPD and Lung Fibrosis, Successfully Completed Phase II Clinical Trials in India on Virus induced lung disease.
PulmiORA: The First-in-Class Therapy Targeting COPD and Lung Fibrosis caused by Virus, Bacterial and Fungal Infections at its Molecular Core – Not just Managing Symptoms, but Restoring Respiratory Health.
People worldwide affected by COPD and Lung Fibrosis
Annual deaths from COPD and Lung Fibrosis globally
Current global market value (2024)
Projected market value by 2032
PulmiORA represents a paradigm shift in COPD and Lung Fibrosis treatment. Unlike traditional therapies that only suppress symptoms, our innovative approach targets the root cause at the molecular level.
First-in-class therapy that oxidizes pathogen genetic material, eliminating bacteria, viruses, and fungal fibrosis in the respiratory system.
Safe, controlled nebulization delivery with almost no side effects compared to steroids and antibiotics.
The most cost-effective COPD and Lung Fibrosis treatment available, making it accessible to patients worldwide.
Our groundbreaking mechanism of action is protected by Indian patent, ensuring exclusive innovation.
Actively prevents lung tissue damage and promotes restoration of healthy respiratory function.
Short 3-5 day treatment protocol with high patient compliance and convenience.
Explore our research, treatment protocols, and the distinguished scientific heritage behind this breakthrough therapy.
